ACLX News and Press, Arcellx Inc. From 04/24/23

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference PR Newswire REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development o...

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights PR Newswire -- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-te...

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference PR Newswire REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovativ...

H.C. Wainwright has initiated Arcellx ( NASDAQ: ACLX ) with a buy saying that the company's CAR-T therapies in development have advantages over marketed ones and its partnership with Gilead Sciences' ( GILD ) Kite Therapeutics will reap benefits. The firm has a $42 price target (~...

Arcellx to Participate in Upcoming Investor Conferences PR Newswire REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patien...

Gilead Sciences' ( NASDAQ: GILD ) Kite unit and Arcellx ( NASDAQ: ACLX ) have finalized a collaboration for the further development of CART-ddBCMA, the latter company's lead treatment for relapsed or refractory multiple myeloma. The T-cell therapy, currently in phase 2, will b...

Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatme...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead. Arcellx goes up against Johnson & Johnson's formidable carvykti, but now it has help. Arcellx, Inc. ( ACLX ) is up 83% since my bullish coverage f...